Enterprise Therapeutics
Respiratory diseases drugs manufacturer.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
* | $26.0m Valuation: $145m | Series B | |
| Total Funding | 000k | ||
| GBP | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 9 % | 821 % | 29 % | 14 % | (96 %) | - | - |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (6321 %) | (1118 %) | (609 %) | (432 %) | (10426 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (5454 %) | (911 %) | (544 %) | (342 %) | (8834 %) | (9043 %) | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 1 % | - | 2 % | - | - |
Source: Company filings or news article
Related Content
Enterprise Therapeutics is a biotechnology company specializing in the discovery and development of novel treatments for respiratory diseases. The company operates in the pharmaceutical and biotech sectors, targeting conditions such as cystic fibrosis and other chronic respiratory diseases. Enterprise Therapeutics collaborates with leading scientific experts and renowned physicians to advance its therapeutic approaches. The company’s business model revolves around the research and development of proprietary drugs, which are then licensed to larger pharmaceutical companies for commercialization. Revenue is generated through licensing agreements, milestone payments, and royalties from drug sales. Enterprise Therapeutics serves a global market, primarily focusing on patients suffering from severe respiratory conditions. The company is backed by a blend of corporate and traditional venture investors, including Novartis Venture Fund, Versant, Forbion, IP Group, and Epidarex, who bring extensive experience in pharma and biotech industries.
Keywords: biotechnology, respiratory diseases, cystic fibrosis, drug discovery, drug development, licensing, milestone payments, royalties, venture investors, pharmaceutical.